Q-omics provides the consensus-scored BTBD2 profile across patient tissues and cancer cell-line models. BTBD2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BTBD2 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, BTBD2 protein abundance shows 21,386 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight ACC, KIRP, and CCRCC as cancer lineages where BTBD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTBD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTBD2 survival associations across molecular data types. BTBD2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTBD2 RNA expression–survival associations across cancer types. High BTBD2 expression shows unfavorable associations in ACC, KICH and LIHC, but favorable associations in SCLC, HNSC and CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BTBD2 RNA expression.
This table summarizes BTBD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BTBD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTBD2 shows higher tumor expression in KIRP, KIRC, COAD, HNSC, LIHC and LUSC. The KIRP box plot shows higher BTBD2 RNA expression in tumor versus normal tissue (log2 FC = +0.649, t-test p < 0.001).
This table shows molecular features associated with BTBD2 in patient tissues and cancer cell lines. In patient samples, BTBD2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BTBD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
